Prof Danny Rischin
Honorary Conjoint Professorial Fellow
The Sir Peter MacCallum Department of Oncology
532 Scholarly works
8 Projects
HIGHLIGHTS
2026
Journal article
PD-L1 CPS ≥10 population subgroup analysis of KEYNOTE-412: Pembrolizumab plus chemoradiotherapy versus placebo plus chemoradiotherapy for unresected locally advanced head and neck squamous cell carcinoma.
DOI: 10.1200/jco.2026.44.16_suppl.60632026
Journal article
A multicenter, randomized, double-blind, phase 2/3 study of ficerafusp alfa (BCA101) or placebo in combination with pembrolizumab for first-line treatment of HPV-negative, PD-L1–positive, recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): FORTIFI-HN01.
DOI: 10.1200/jco.2026.44.16_suppl.tps61292026
Journal article
C-POST study of adjuvant cemiplimab for high-risk cutaneous squamous cell carcinoma (CSCC): Disease-free survival (DFS) analyses per high-risk criteria and per start time after radiotherapy.
DOI: 10.1200/jco.2026.44.16_suppl.60832026
Research grants (ARC, NHMRC, MRFF)
Expanding the Role of Immunotherapy in Cutaneous and Mucosal Head and Neck Squamous Cell Carcinomas
2025
Research grants (ARC, NHMRC, MRFF)
Novel Treatment of Radiation Associated Dysphagia With Statins (TRADstat)
2024
Journal article
BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance
DOI: 10.1186/s12943-024-02048-12020
Research grants (ARC, NHMRC, MRFF)
Defining the Role of Immunotherapy and Immune Biomarkers in Head and Neck and Cutaneous Squamous Cell Carcinomas
RECENT SCHOLARLY WORKS
2026
Journal article
FORTIFI-HN01: A Multicenter, Randomized, Double-Blind, Phase 2/3 Study of Ficerafusp Alfa or Placebo in Combination with Pembrolizumab for First-Line Treatment of PD-L1-Positive, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
DOI: 10.1016/j.ijrobp.2026.02.1862026
Journal article
Fianlimab, a human lymphocyte activation gene-3 monoclonal antibody, in combination with cemiplimab: Tumor-specific expansion cohorts in advanced malignancies
DOI: 10.1002/cncr.703962026
Journal article
Clinical and Patient-Reported Outcomes (PROs) in C-POST: Phase 3 Trial of Adjuvant Cemiplimab (Cemi) vs Placebo (Pbo) for High-Risk Cutaneous Squamous Cell Carcinoma (CSCC)
DOI: 10.1016/j.ijrobp.2026.02.1432026
Journal article
Extended follow-up outcomes of patients with advanced cutaneous squamous cell carcinoma treated with cemiplimab on EMPOWER-CSCC-1: A retrospective cohort study
DOI: 10.1016/j.jaad.2025.11.0802026
Journal article
INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
DOI: 10.1158/1078-0432.CCR-25-11972026
Journal article
Prospective Evaluation of Patient Priorities in Human Papillomavirus-Driven Oropharyngeal Cancer Using the Chicago Priorities Scale: Considerations for Future Clinical Trial Design
DOI: 10.1016/j.ijrobp.2025.08.0532026
Journal article
Examining CD103 Tissue-Resident Memory T Cells in Nasopharyngeal Carcinoma
DOI: 10.1002/hed.70026
RECENT PROJECTS
2026
Research grants (ARC, NHMRC, MRFF)
Expanding the Role of Immunotherapy in Cutaneous and Mucosal Head and Neck Squamous Cell Carcinomas